Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease

Stock Information for Organovo Holdings Inc.

Loading

Please wait while we load your information from QuoteMedia.